← Back to all substances
A
metformin
177ms
Level 1
✓ What this shows
- • Reported adverse events from FDA FAERS
- • Descriptive statistics from a locked corpus
- • Data verified with cryptographic hashes
✗ What this is NOT
- • Not medical advice or recommendations
- • Not proof of causality
- • Not a complete safety profile
About this substance
Class: Dipeptidyl Peptidase 4 Inhibitor [EPC]
1 INDICATIONS AND USAGE ZITUVIMET is a combination of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Z...
Known as: ZITUVIMET
Route: ORAL
Source: OpenFDA Drug Labels · Reference only · Not medical advice
500
Events in Corpus
v20260131-01
413,246
Total in FDA
75%
Serious Reports
60
Fatal Outcomes
Seriousness
Serious
374
Non-Serious
126
Sex Distribution
Male
208
Female
266
Unknown
26
Age Distribution
0-17
1
18-40
13
41-64
202
65-84
166
85+
11
Unknown
107
Outcomes
Recovered/Resolved
349
Recovering/Resolving
99
Not Recovered/Not Resolved
259
Recovered with Sequelae
43
Fatal
60
Unknown
834
Top Reported Reactions (click to view reports)
Verification Data
Corpus Version: v20260131-01
Root Hash: ec5727564d1ed19be5b08b26d3866f446b12d3d388f5a8cd713332c6d97ad264
Stats Hash: N/A
EVE Decision ID: EVE-MED-20260402-338342
This output reports adverse events from FDA FAERS. It does not constitute medical advice.
Molecular Structure (reference)
Structural visualization for identification only.
This visualization shows the molecular structure for identification purposes only. It does not represent pharmacological effect, safety, or clinical relevance.
Loading structure...